← Top stories
Legal▼ Bearish for Indian equities
SC flags a costly dose of markups, asks for 16% cap on essential meds
The brief
- Supreme Court asks Centre why essential medicines could not have a 16% MRP cap
- A price cap could constrain pricing and margins for Indian pharmaceutical companies
- Advent International seeks CCI green channel clearances for Yatharth Hospital stake buy
- Two Trades for Today: 2 mid-cap pharma stocks, one for a rise of 6.2%, and the other for a gain of almost 7%
- India's ageing transition will be faster than in US, Indonesia: Moody's
- IHH plans to raise Fortis stake to 51%, expand capacity to 10K beds by 2031
- PE/VC investments jump 98% in August as large deals drive activity
Price controls on patented and essential medicines
The Kerala High Court said the government may intervene over prohibitively priced patented medicines and directed the Centre to gather information. The Supreme Court later asked why essential medicines could not have a 16% cap on maximum retail prices.
Tuesday, 29 September
- SC flags a costly dose of markups, asks for 16% cap on essential meds